We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Molecular Scaffolds Promise Drug Synthesis in Breast Cancer Treatment

By LabMedica International staff writers
Posted on 16 Oct 2018
A recently developed class of molecular scaffolds for treatment of breast cancer promises to facilitate the synthesis of drugs capable of degrading or inhibiting estrogen receptors (ERs).

Drug developers have been searching for compounds with selective estrogen receptor degrader (SERD) and ER antagonistic properties for many years. More...
A SERD is a type of drug that binds to the ER and, in the process of doing so, causes the ER to be degraded and thus downregulated. They are used to treat estrogen receptor-sensitive or progesterone receptor-sensitive breast cancer, along with older classes of drugs like selective estrogen receptor modulators (SERMs) and aromatase inhibitors. To date, the only SERD approved for marketing in the USA has been Fulvestrant, which works by binding to the ER and destabilizing it, causing the cell's normal protein degradation processes to destroy it.

Investigators at the Stevens Institute of Technology (Hoboken, NJ, USA) reported in the August 9, 2018, issue of the journal ACS Medicinal Chemistry Letters that they had developed new classes of scaffolds that possess SERD and ER antagonistic properties. These novel SERDs potently inhibited MCF-7 breast cancer cell proliferation and the expression of ER target genes, and their efficacy was comparable to Fulvestrant.

Unlike Fulvestrant, the modular protein-targeted chimera (PROTAC)-type design of these novel SERDs is expected to allow easy diversification into a library of analogs to further fine-tune their pharmacokinetic properties including oral availability. In addition, this will tend to expand the pool of currently available PROTAC-type scaffolds that could be beneficial for targeted degradation of various other therapeutically important proteins.

“The unique benefit of our compounds is that this is a fundamentally different type of structure that was previously not known to degrade or inhibit estrogen receptors,” said senior author Dr. Abhishek Sharma, professor of chemistry at the Stevens Institute of Technology. “It is not a tweak of an existing drug; it works in a completely different way. We consider these results to be very promising. This is a novel molecular structure, and several analogs produced excellent early activity."

Related Links:
Stevens Institute of Technology


New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.